BRAF and melanoma: Growth inhibition assays on SKMEL28 and CHL-1 cells showed no major differences in the potency of 17-AAG between the two cell lines, consistent with previous studies in larger panels showing that mutant BRAF is not a predictive marker for sensitivity to Hsp90 inhibitors in human melanoma cell lines [20, 21].